Key Highlights
● CI closed at $282.24 on 9 October 2026, and the $338.24 consensus target implies upside of about 19.8%.
● The consensus draws on 23 analysts, with targets from $290 to $400, while the second data set shows a $342.29 mean from 24 analysts.
● Market data records 15 Buy and eight Hold ratings with no Sell, a Moderate Buy consensus.
● Piper Sandler lifted its target to $370 from $346 on 2 October, while Evercore initiated at In-Line with a $290 target on 9 September.
The Cigna Group (NYSE:CI), a constituent of the S&P 500, closed at $282.24 on Friday 9 October 2026. Analysts who cover the health insurer and pharmacy-benefits operator generally sit above that level, with the consensus price target at $338.24.
What Is the Latest Analyst Price Target?
According to market data, 23 analysts have published ratings on Cigna in the past 12 months. Their average target of $338.24 implies roughly 19.8% upside from the $282.24 close, within a range of $290 to $400. The second data set, which draws on third-party data, shows a slightly higher mean of $342.29, a median of $345, a high of $400 and a low of $288 from 24 analysts.
What Are Wall Street Analysts Saying?
Market data records 15 Buy ratings, 8 Hold ratings and no Sell ratings, giving a consensus of Moderate Buy. The second data set reports a similar skew, with 18 Buy or Strong Buy ratings, six Holds and no Sells.
Recent broker activity has been mixed in tone but mostly constructive. On 2 October 2026 Piper Sandler lifted its target from $346 to $370 with an Overweight rating, and Bernstein reiterated Outperform. On 1 October Royal Bank of Canada reiterated Outperform with a $337 target and UBS reiterated Buy. Evercore initiated coverage on 9 September with an In-Line rating and a $290 target, the lowest on the market data list. After the most recent quarterly results, Jefferies downgraded the shares from Buy to Hold on 4 August (target cut from $336 to $307) and Raymond James moved from Strong Buy to Outperform on 3 August (target $350 to $320). Guggenheim raised its target from $338 to $361 around 31 July.
What Could Help the Stock Reach the Price Target?
Market data cites for the latest quarter earnings per share of $7.78 against a consensus of $7.60 and revenue of $71.56 billion against $70.14 billion expected. If the company keeps beating estimates, analysts may feel more comfortable with their higher targets.
What Could Prevent the Stock Reaching the Target?
Targets can be revised downwards, and the range is wide: the highest at $400 is more than 40% above the share price, while the lowest at $288 implies only about 2% upside. Health insurers face regulatory scrutiny, medical cost trends and policy changes that can alter earnings quickly. The two downgrades after the last results show that some analysts have become more cautious.
What Should Investors Watch Next?
Items to watch include changes in broker targets after that report, any updates to company guidance and developments in health policy that affect insurers and pharmacy-benefit managers.
Cigna's Wide Target Range Includes Both a 40% Upside Call and a 2% One
Cigna closed at $282.24 on 9 October 2026, with the $338.24 consensus target about 19.8% higher, but the range is wide: the highest target of $400 is more than 40% above the share price, while the lowest at $288 implies only about 2% upside. Broker activity is mixed in tone but mostly constructive, with Piper Sandler's raise and Bernstein's Outperform alongside the August downgrades from Jefferies and Raymond James. Health policy and medical cost trends can alter earnings quickly.






Please wait processing your request...